Vorinostat (SAHA)

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Unravel Biosciences, Inc.

Conditions

LymphomaNeuroblastomaPitt Hopkins SyndromeRett SyndromeSarcomaWilmsTumor

Phase 1

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

CompletedNCT01132911

National Cancer Institute (NCI)Lymphoma, Neuroblastoma, Sarcoma +1

Start: 2010-05-10End: 2011-04-13Target: 5Updated: 2017-07-02

Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome

RecruitingNCT07150013

Unravel Biosciences, Inc.Rett Syndrome

Start: 2026-03-15End: 2027-03-15Target: 15Updated: 2026-09-17

An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome

RecruitingNCT07150026

Unravel Biosciences, Inc.Pitt Hopkins Syndrome

Start: 2026-03-15End: 2027-03-15Target: 5Updated: 2026-09-17